

# Tackling heart disease: the Scottish aspirin trial

<b>Submission date</b> 31/01/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/01/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/02/2015	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof FGR Fowkes

### Contact details

Wolfson Unit for Prevention of Peripheral Vascular Diseases  
University of Edinburgh  
Teviot Place  
Edinburgh  
United Kingdom  
EH8 9AG  
+44 (0)131 650 3219  
Gerry.Fowkes@ed.ac.uk

### Type(s)

Public

### Contact name

Dr Jackie Price

### Contact details

Community Health Sciences  
University of Edinburgh Medical School  
Teviot Place  
Edinburgh  
United Kingdom  
EH8 9AG

## **Additional identifiers**

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

RG/97006; 057762

## **Study information**

### **Scientific Title**

Randomised controlled trial of low dose Aspirin in the prevention of cardiovascular events and death in subjects with Asymptomatic Atherosclerosis

### **Acronym**

AAA Trial

### **Study objectives**

Primary prevention strategies aimed at modifying cardiovascular risk factors in otherwise healthy individuals have proved of only limited benefit in the primary prevention of cardiovascular disease. It is possible to identify in the general population large numbers of subjects with asymptomatic preclinical atherosclerosis who are at high risk of subsequent cardiovascular events using a simple blood pressure measurement - the Ankle Brachial Pressure Index (ABPI). We are currently conducting the first prevention trial on such high-risk subjects to determine whether low dose aspirin can reduce the incidence of cardiovascular events and death. 3,350 subjects aged over 50 years with an ABPI of at least 0.95 but no history of cardiovascular disease have been randomised into this double-blind placebo-controlled trial.

The principal hypothesis is that treatment of subjects with asymptomatic atherosclerosis, using low-dose aspirin, prevents subsequent cardiovascular disease indicated by incidence of major cardiovascular and cerebrovascular events.

An additional endpoint was added to this trial shortly after funding was obtained for the original AAA trial. As this additional endpoint has little to do with cardiovascular disease, funding was sought, and gained, from the Wellcome Trust. This end point was known as the 'Randomised controlled trial of aspirin in the reduction of age associated cognitive decline', and any information relating only to this endpoint will be headed with the title: 'Cognitive decline endpoint'

The aim of this endpoint is to determine whether low dose aspirin treatment over a five-year period reduces cognitive decline in subjects at high risk of cardiovascular disease.

### **Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

AAA Trial:

1. Lanarkshire Research Ethics Committee: date of approval 22/04/1997 (ref: ER/4/97/8)
2. Greater Glasgow Community/Primary Care Local Research Ethics Committee: date of approval 14/06/1999 (ref: 45A/99)
3. Lothian Research Ethics Committee: date of approval 31/05/1999 (ref: 1702/99/3/23)

Cognitive Study:

1. Lanarkshire Research Ethics Committee: date of approval 26/10/1999 (ref: ER/49/10/99)
2. Greater Glasgow Community/Primary Care Local Research Ethics Committee: details as for AAA Trial (see above)
3. Lothian Research Ethics Committee: amendment to AAA Trial made and approved on 11/10/1999

**Study design**

Randomised placebo-controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Other

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Cardiovascular disease, cognitive decline

**Interventions**

100 mg enteric-coated aspirin daily for five years or placebo daily for five years

The trials were initially designed to end simultaneously, but follow-up in the AAA Trial has been extended (with corresponding supplementary funding from BHF and CSO) to obtain the required number of major cardiovascular endpoints. Similar power considerations were not necessary for the cognitive decline endpoint; therefore the end date for the cognitive decline endpoint is 31/04/2006.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Aspirin

**Primary outcome measure**

Myocardial infarction and stroke (fatal and non-fatal) or revascularisation

**Cognitive decline endpoint:**

A detailed battery of tests was administered to assess a broad range of the participants' cognitive functions. The test battery was administered in a quiet room either in the clinic or at the patient's home by a trained researcher. The order of tests in the battery was predetermined. The Mini Mental State Examination (MMSE) was included as a general mental assessment and as a 'screen' for dementia. Executive function was assessed with use of the Verbal Fluency Test, which requires participants to generate as many words as possible with a specified initial letter (C, F and L).

As a measure of non-verbal reasoning, participants were asked to work through all five sets (A to E) of the Raven's Progressive Matrices, and were scored according to the number of items they completed correctly within 20 minutes. Immediate and delayed memory was assessed using a participant's total score on the first five trials (I through V) of the Auditory Verbal Learning Test.

As a measure of mental flexibility, the Trail Making Test was administered and the time taken to complete part B was used in the subsequent analysis. In the Digit Symbol Test, used as a measure of speed of information processing, the number of symbols matched correctly to their corresponding numbers in 90 seconds was recorded.

The Hospital Anxiety and Depression Scale (HAD A and HAD D) was also used for the assessment of mood states, as these can affect performance on the tests, and the National Adult Reading Test (NART) was used to estimate Intelligence Quotient (IQ).

**Secondary outcome measures**

1. Total cardiovascular mortality
2. All cause mortality
3. Angina
4. Intermittent claudication
5. Transient ischaemic attack
6. Side effects/adverse events

**Overall study start date**

01/04/1998

**Completion date**

31/12/2009

**Eligibility****Key inclusion criteria**

1. Men and women aged between 50 and 80 years
2. Ankle brachial pressure index 0.95 or less in at least one limb
3. Living in central Scotland (Lothian, Greater Glasgow and Lanarkshire)
4. No history of clinical cardiovascular disease

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Both

**Target number of participants**

3350

**Key exclusion criteria**

1. Receiving aspirin and/or other anticoagulants
2. Contraindication to aspirin therapy

**Date of first enrolment**

01/04/1998

**Date of final enrolment**

01/02/2002

**Locations****Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

**Wolfson Unit for Prevention of Peripheral Vascular Diseases**

Edinburgh

United Kingdom

EH8 9AG

**Sponsor information****Organisation**

University of Edinburgh (UK)

**Sponsor details**

ACCORD Office

The Queen's Medical Research Institute

47 Little France Crescent

Edinburgh

Scotland  
United Kingdom  
EH16 4TJ

**Sponsor type**  
University/education

**Website**  
<http://www.ed.ac.uk/>

**ROR**  
<https://ror.org/01nrxf90>

## **Funder(s)**

**Funder type**  
Charity

**Funder Name**  
British Heart Foundation (UK) (ref: RG/97006)

**Alternative Name(s)**  
the\_bhf, The British Heart Foundation, BHF

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
Trusts, charities, foundations (both public and private)

**Location**  
United Kingdom

**Funder Name**  
Chief Scientist Office (CSO) (UK) (ref: K/OPR/2/2/D320)

**Alternative Name(s)**  
CSO

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
Local government

**Location**

United Kingdom

**Funder Name**

Wellcome Trust

**Alternative Name(s)****Funding Body Type**

Private sector organisation

**Funding Body Subtype**

International organizations

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2008		Yes	No
<a href="#">Results article</a>	results	03/03/2010		Yes	No
<a href="#">Results article</a>	results	11/01/2011		Yes	No